Psychotherapeutic Drugs Chapter 16 Flashcards
alprazolam** (Xanax)
CLASS/ INDICATIONS
PSYCHOTHERAPEUTIC DRUGS: Chapter 16
CLASS: benzodiazepines
INDICATIONS: anxiety, panic disorder
alprazolam** (Xanax)
DOSAGES
PO: 0.25-2 mg tid; do not exceed 4 mg/day ADULT
alprazolam** (Xanax)
ADVERSE EFFECTS
amnesia, anorexia, sedation, lethargy, fatigue, confusion, drowsiness, dizziness, ataxia, headache, visual changes, hypotension, weight gain or loss, nausea, weakness
alprazolam** (Xanax)
NURSING IMPLICATIONS/ CONTRAINDICATIONS
Schedule IV: addictive
alprazolam** (Xanax)
DRUG INTERACTIONS
Additive effects: enhanced CNS depression, sedation, confusion, ataxia (CNS depressants: alcohol, opioids)
Impaired hepatic elimination of benzodiazepine: enhanced benzodiazepine effects: CNS depression (oral contraceptives, azole antifungals, SSRIs, verapamil, diltiazem, opioids, valproic acid)
Enhanced benzodiazepine clearance: reduced therapeutic effects (rifampin)
Antagonistic effects: reduced sedative effects (theophylline)
Reduced clearance: potential for digoxin toxicity (phenytoin)
amitriptyline** (Elavil)
CLASS/ INDICATIONS
PSYCHOTHERAPEUTIC DRUGS: Chapter 16
CLASS: Tricyclic
INDICATIONS: depression, insomnia, neuropathic pain
amitriptyline** (Elavil)
DOSAGES
PO: 10-300mg/ day ADULT
amitriptyline** (Elavil)
ADVERSE EFFECTS
Anorexia, dry mouth, blurred vision, constipation, gynecomastia, sexual dysfunction, altered blood glucose level, urinary retention, agitation, anxiety, ataxia, cognitive impairment, sedation, headache, insomnia, skin rash, photosensitivity, weigh changes, orthostatic hypotension, blood dyscrasias
amitriptyline** (Elavil)
NURSING IMPLICATIONS/ CONTRAINDICATIONS
NI: cuases constipation, blurred vision, urinary retention, dysrhythmias
CT: drug allergy, pregnancy, myocardial infarction
amitriptyline** (Elavil)
DRUG INTERACTIONS
Enhanced TCA clearance: reduced therapeutic effects (carbamazepine, rifamycins
Reduced carbamazepine clearance: potential for carbamazepine toxicity (carbamazepine)
Enhance serotonergic effects: potential for serotonin syndrome (MAOIs)
Reduced TCA clearance: potential for TCA toxicity (valproic acid)
Additive anticholinergic effects: potential for paralytic ileus (anticholinergics)
Enhanced sympathomimetic effects: potential for cardiac dysrhythmias (sympathomimetics)
bupropion** (Wellbutrin, Zyban)
CLASS/ INDICATIONS
PSYCHOTHERAPEUTIC DRUGS: Chapter 16
CLASS: Miscellaneous
INDICATIONS: depression (Wellbutrin), smoking cessation (Zyban)
bupropion** (Wellbutrin, Zyban)
DOSAGES
PO: 200-300 mg/day divided bid
PO, SR: 150-300 mg/ day
bupropion** (Wellbutrin, Zyban)
ADVERSE EFFECTS
Dizziness, headache, sedation, nausea, blurred vision, tachycardia
bupropion** (Wellbutrin, Zyban)
NURSING IMPLICATIONS/ CONTRAINDICATIONS
CT: known drug allergy, seizure disorder, anorexia nervosa, bulimia, MAOIs.
bupropion** (Wellbutrin, Zyban)
DRUG INTERACTIONS
Impaired hepatic metabolism: increased effects (azole antifungals, phenothiazines, protease inhibitors)
Increased metabolism: decreased therapeutic effects (carbamazepine)
Additive effects: increased CNS depression (alcohol, CNS depressants)
diazepam** (Valium)
CLASS/ INDICATIONS
PSYCHOTHERAPEUTIC DRUGS: Chapter 16
CLASS: benzodiazepines
INDICATIONS: anxiety
diazepam** (Valium)
DOSAGES
PO: 2-10 mg 2-3 times/day ADULT
PO: 1-2.5 mg 3-4 times/day PEDIATRIC
diazepam** (Valium)
ADVERSE EFFECTS
amnesia, anorexia, sedation, lethargy, fatigue, confusion, drowsiness, dizziness, ataxia, headache, visual changes, hypotension, weight gain or loss, nausea, weakness